NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

VYNE Therapeutics Inc. (VYNE) Stock Analysis

VYNE Therapeutics Inc. (VYNE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

VYNE

$28.56

+$3.11 (+12.22%)

Last trade July 27, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VYNE with… →

VYNE Key Statistics

As of Jul 27, 2026
Trading
Open
$25.50
Previous Close
$25.45
Day's Range
23.37–28.56
52-Week Range
14.03–46.95
Volume
93.26K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.01
Valuation
Market Cap
$19.07M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
42.00
EPS (ttm)Profit attributable to each share over the last twelve months.
−27.58
Financials (FY)
Revenue (FY)
$570.00K+13.77%
Net Income (FY)
−$26.48M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+1856.16%
Dividend and dates
Avg Volume
17.72K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

VYNE Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4824.14%
2025−80.79%

As of July 27, 2026.

VYNE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$570.00K−$26.48M−4646.1%
2024$501.00K−$39.83M−7950.9%
2023$424.00K−$28.45M−6710.4%
2022$477.00K−$23.21M−4865.8%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$570.00K—−$29.75M−$26.48M−4646.1%
2024$501.00K—−$43.64M−$39.83M−7950.9%
2023$424.00K—−$29.26M−$28.45M−6710.4%
2022$477.00K—−$34.30M−$23.21M−4865.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VYNE Valuation vs Biotechnology Median

Median of 656 stocks
MetricVYNEBiotechnology medianvs median
P/S ratio42.0015.26175% above
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values VYNE Therapeutics Inc. (VYNE) at $19.07M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 10.

The 52-week range on file runs from $14.03 to $46.95. The most recent close on file for VYNE is $28.56, dated July 27, 2026. That is +$3.11 (+12.22%) against the previous close. The latest close sits 103.64% above that 52-week low.

Financial Health

In fiscal 2025, VYNE Therapeutics Inc. reported revenue of $570.00K. Against the prior fiscal year total of $501.00K, that is a change of +13.77%. The same year closed with a net loss of $26.48M. Profit margin runs at 0%. Trailing earnings per share are −27.58.

Across the 4 fiscal years on file, revenue moves from $477.00K in 2022 to $570.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 42 times revenue. On price-to-sales that is 175.19% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 2.01. Annualized volatility over the trailing 1 year is 5,101.9%. The trailing one-year price return is +1,856.16%. The stored price history starts on January 13, 2025, and the total return since then is +845.70%.

Growth & Income

No dividend is on file for VYNE.

2026 is still running; the price is +4,824.14% year to date. The record holds one complete calendar year, 2025, which returned −80.79%.

Peer Comparison

VYNE Therapeutics Inc. (VYNE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
VYNE Therapeutics Inc. VYNE $19.07M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. VYNE Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 27, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.

Visit website →